A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma

Overview of attention for article published in Oncologist, September 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news: 1 news outlet
twitter: 21 X users

facebook: 1 Facebook page

So far, Altmetric has seen 30 X posts from 21 X users, with an upper bound of 257,141 followers.

A Phase I Study of Alpha‐1,3‐Galactosyltransferase‐Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma https://t.co/7Z5yEK7z0k https://t.co/eCbWuhDqMN

RT @montypal: I don't know too many 1st yr fellows publishing 1st author clinical trial papers. Kudos to @OncHahn for his stellar work/enth…

RT @OncHahn: In a phase 1 trial in @OncJournal, an RCC vaccine w/ a novel MOA was well-tolerated alone or with nivo in pts w/ mRCC progress…

RT @NatRevClinOncol: In a phase I study of HyperAcute Renal immunotherapy (two allogeneic RCC lines genetically modified to express α(1,3)…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 26 additional X posts.